FDA Accepts sBLA for Frontline Atezolizumab Plus Carboplatin/Nab-Paclitaxel in Nonsquamous NSCLC

January 17, 2019 – The FDA has accepted a supplemental biologics license application (sBLA) for atezolizumab, carboplatin, and nab-paclitaxel as a first-line treatment for patients with metastatic nonsquamous non–small cell lung cancer (NSCLC). The sBLA is based on data from the phase III IMpower130 trial, which demonstrated a statistically significant improvement in both progression-free and overall survival (OS) compared with chemotherapy alone … (leggi tutto)